Selecta Biosciences to Participate at the H.C. Wainwright 23rd Annual Global Investment Conference
Selecta Biosciences, Inc. (NASDAQ: SELB) announced that CEO Carsten Brunn, Ph.D., will provide a corporate update at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. The presentation will be available on-demand starting at 7:00 a.m. ET on September 13. Selecta is focused on developing tolerogenic therapies utilizing its ImmTOR™ platform to address unwanted immune responses. The company's pipeline includes enzyme therapies, gene therapies, and treatments for autoimmune diseases.
- None.
- None.
WATERTOWN, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Selecta’s Chief Executive Officer, Carsten Brunn, Ph.D., will provide a corporate update and participate in one-on-one investor meetings at the H.C. Wainwright 23rd Annual Global Investment Conference to be held September 13-15, 2021.
The presentation will be available on-demand through the H.C. Wainwright conference portal, starting at 7:00 a.m. ET on Monday, September 13, 2021.
An archived webcast of the presentation will be accessible in the Investors & Media section of the company’s website at www.selectabio.com.
About Selecta Biosciences, Inc.
Selecta Biosciences Inc. (NASDAQ: SELB) is a clinical stage biotechnology company leveraging its ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses. With a proven ability to induce tolerance to highly immunogenic proteins, ImmTOR has the potential to amplify the efficacy of biologic therapies, including redosing of life-saving gene therapies, as well as restore the body’s natural self-tolerance in autoimmune diseases. Selecta has several proprietary and partnered programs in its pipeline focused on enzyme therapies, gene therapies, and autoimmune diseases. Selecta Biosciences is headquartered in the Greater Boston area. For more information, please visit www.selectabio.com.
For Investors:
Bruce Mackle
LifeSci Advisors, LLC
+1-929-469-3859
bmackle@lifesciadvisors.com
For Media:
Brittany Leigh, Ph.D.
LifeSci Communications, LLC
+1-646-751-4366
bleigh@lifescicomms.com
FAQ
When will Selecta Biosciences present at the H.C. Wainwright 23rd Annual Global Investment Conference?
How can I access Selecta Biosciences' presentation from the conference?
What is the focus of Selecta Biosciences' ImmTOR™ platform?
What types of therapies is Selecta Biosciences developing?
Where is Selecta Biosciences headquartered?
